GeneDx Holdings (NASDAQ:WGS) reported fourth-quarter 2025 results on Monday that underscored its successful pivot to a high-margin, "genomic-first" business model.
The Gaithersburg-based leader in rare disease diagnostics delivered $121 million in revenue, hitting the top end of its preliminary estimates and recording a 32% increase in its core exome and genome testing segment.
More significantly, the company achieved adjusted net income of $4.4 million, marking a major step toward sustained profitability.
The quarterly performance was characterized by a sharp acceleration in testing volume, which grew 34% year-over-year.
This growth was driven by deepening penetration into the pediatric and neurology markets, as well as the initial rollout of GeneDx Infinity™, the company’s AI-driven platform that leverages the world's largest rare disease genomic dataset.
Despite the exclusion of a one-time 2024 payer benefit that skewed year-over-year comparisons, the underlying "normalized" growth for the exome and genome business reached an impressive 42%.
"GeneDx is uniquely positioned to deliver for patients, clinicians, and partners—and our results demonstrate that," said CEO Katherine Stueland, who was recently named to the 2026 TIME100 Health list.
"Our team is executing at the highest level, our platform continues to scale, and our data advantage strengthens with every test we run."
Stueland noted that the company enters 2026 with its strongest-ever balance sheet, finishing the year with $172 million in cash and marketable securities.
Looking ahead, GeneDx reaffirmed its full-year 2026 guidance, projecting total revenue between $540 million and $555 million.